The role of Th9 cells in these adverse events is not explored, but predicated on the reported ramifications of ICI therapy over the Th9 population
Structure-Based Design of mTORC1 Inhibitors in Cancer Therapy
mTORC1 inhibitor
mTORC1 inhibitor
The role of Th9 cells in these adverse events is not explored, but predicated on the reported ramifications of ICI therapy over the Th9 population